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Abstract 
Background: Colorectal cancer (CRC) is one of the leading causes of mortality and morbidity. The Kashmir valley, in Northern India, has 
been described as a high-risk area for colorectal cancer.  
Aim: The aim was to make a preliminary attempt to study mutations in exons 5–8 (the DNA binding domain) of the tumour suppressor 
gene TP53 in 42 CRC patients from Kashmir.  
Materials and methods: The study population consisted of 42 patients diagnosed with colorectal cancer. Mutations in exons 5–8 of the 
TP53 gene were detected by means of single-strand conformation polymorphism (SSCP). All samples that showed different band 
migration patterns in the SSCP were confirmed by sequencing.  
Results: The 28 mutations were found in the TP53 gene in 19 patients, comprised 23 substitutions (17 transitions + six transversions), 
and five insertions. The 23 substitutions represent 18 missense mutations, leading to amino acid substitutions, two nonsense mutations, 
leading to stop codons, while the remaining three were silent mutations. The five insertions represented frameshifts. Two of 28 mutations 
(7.14%) have not been previously reported in colon cancer samples and were identified as novel TP53 mutations. Comparison of the 
mutation profile with other ethnic populations and regions reflected both differences and similarities indicating co-exposure to a unique 
set of risk factors.  
Conclusions: Mutation of the TP53 gene is one of the commonest genetic changes in the development of human colorectal cancer. The 
high frequency of TP53 gene mutations implicates TP53 as a predominant factor for colorectal cancer in the high-risk ethnic Kashmir 
population. 
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Introduction 
Colorectal cancer (CRC) is the third most common cause of 
cancer-related death in the western world. The annual incidence 
of CRC worldwide has been estimated to be at least half a 
million [1]. It is a commonly diagnosed cancer in both men and 
women. In 2008, an estimated 148,810 new cases will be 
diagnosed, and 49,960 deaths from colorectal cancer will occur 
[2]. The development of CRC is a multi-step process, which can 
arise due to the accumulation of mutations in various different 
oncogenes, tumour suppressor genes and/or from epigenetic 
changes in DNA [3]. Recent progress made in the field of 
molecular biology has shed light on the different alternative 
pathways involved in the colorectal carcinogenesis, and more 
importantly the crosstalk among these pathways [4,5]. 
Mutations in the TP53 tumour suppressor gene are identified in 
approximately 35–45% of CRC [6,7,8,9], and it may be 
associated with worse prognosis and chemo/radio resistance 
[10,11]. 
TP53 mutations are the most frequently detected genetic 
alteration in human cancer [12,13]. The TP53 gene is located 
on the short (p) arm of chromosome 17, and 17p deletions are 
found in 6–25% of colonic adenomas and in as many as 75% of 
colonic carcinomas [14,15]. The TP53 gene encodes a protein, 
which maintains genomic integrity by inducing cell cycle arrest 
and apoptosis when DNA is damaged [16]. Mutations in TP53 
gene occur in almost half of all CRCs, proposed as a late event 
in the transition of an adenoma to carcinoma [17]. The 
mutations in TP53 are thought to cause an increase in the half-
life of the protein, and in one study [18] are associated with its’ 
over-expression in the nucleus. Also, most of the mutations in 
TP53 gene occur in exons 5–8, in highly preserved regions, and 
in the three main structural domains of the TP53 protein (L2, L3 
and the loop-sheet-helix [19]. These mutations cause the 
synthesis of a stable protein that loses the ability to bind DNA 
and activation of target genes [20]. Eighty per cent of the 
alterations that occur in CRC are nonsense mutations: GC to 
TC transitions occurring in CpG dinucleotides [21]. 
The effect that the different alterations located in the different 
exons on the prognosis of patients with CRC has not been 
widely studied, although Borrensen-Dale et al showed that the 
mutations affecting the L3 loop were related with a worse 
prognosis [19]; nevertheless, other authors have not been able 
to confirm these conclusions [22]. Other studies suggest that 
the different mutations in TP53 mat affect the sensitivity of the 
tumours to treatment. 
Therefore, the aim of our study was to assess the contribution 
of  TP53 gene mutations in incidence and development of 
colorectal cancer in patients from the Kashmir valley, since such 
data from this region are not available in the literature. 
Furthermore, we compared the mutation pattern in TP53 from 
the present study with the International Agency for Research on 
Cancer (IARC) TP53 database, as well as the data reported 
from various regions to dissect out the differences and 
similarities in the mutation profile. 
 
Materials and methods 
Patient specimens 
From 56 patients who were diagnosed with CRC by clinicians 
using sigmoidoscopy and colonoscopy, tissue specimens from 
42 colorectal cancers were obtained with consent from patients 
who underwent curative surgical resection from January 2005 to 
2007 at the Department of General Surgery, Sher-I-Kashmir 
Institute of Medical Sciences, Srinagar, India. An experienced 
pathologist selected a representative tumour block and 
surrounding normal mucosal tissue block for each case. The 
patient group included 13 women and 29 men with ages ranging 
from 55 to 82 years. Overall, 22 tumours were localized in the 
colon and 20 in the rectum. Clinical diagnosis was confirmed in 
all cases by histological examination. The study protocol was 
approved by the Research Ethics Committee of the Sher-I-
Kashmir Institute of Medical Sciences. 
DNA isolation 
Genomic DNA was extracted from single-cell suspension of 
blood and tissue samples of colorectal cancer patients by 
standard Proteinase-K digestion and phenol/chloroform 
extraction for examining mutations in TP53 [23]. 
PCR-SSCP analysis 
Exons 5–8 of the TP53 gene encoding the DNA binding domain 
were amplified using four specific oligonucleotide primers (Table 
1). PCR was performed in a 25-μl total volume reaction mixture 
containing 50 ng of genomic DNA, 100 ng of each primer, 100 
μM of each NTP, 1.5 mM MgCl2, 1X of Taq buffer and 0.1 unit 
of Taq DNA polymerase (Fermentas). PCR was performed 
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Table 1: Primers used for screening different exons of TP53 
using the following conditions: initial denaturation at 95°C for 
two minutes, 35 cycles of denaturation at 95°C, annealing at 
52–62°C (see Table 1) and extension at 72°C for one minute 
each and final extension at 72°C for 5 minutes in Biorad cycler. 
Negative controls (DNA was replaced with water) were 
amplified by PCR and included in each experiment. The PCR 
products were separated on a 2% agarose gel and analysed 
under a UV illuminator. 
The SSCP analysis of the amplicons of exons 5–8 was 
performed on 6% non-denaturing polyacrylamide gels (PAGE), 
utilizing either non-radioactive silver staining or radioactive 
procedures [24,25]. For non-radioactive SSCP analysis [26], 
PCR products in denaturing buffer (95% formamide, 10-mM 
NaOH, 0.05% xylene-cyanol FF and 0.05% bromophenol blue) 
in 1:1 ratio were heat denatured at 95°C for five minutes, 
immediately cooled on ice for 20 minutes and 6 µl of each was 
loaded onto a 6% PAGE and electrophoresed in 0.5X Tris-
borate EDTA buffer at ±17°C at 4 W constant power for 18–22 
hours. Gels were then silver stained. For radioactive SSCP 
analysis, radio-labelled PCR products  (using α32-pCTP)  were 
added to denaturing buffer   (95% formamide, 20 mM EDTA, 
0.05% xylene-cyanol FF and 0.05% bromophenolblue) in a 1:10 
ratio and were heat denatured at 95°C for 5 minutes, 3 µl of 
which were loaded on 6% PAGE and electrophoresed at 4 W in 
0.5X Tris-borate EDTA buffer at ±17°C for 18–22 hours. PCR-
SSCP analysis was repeated twice for each sample to minimize 
the possibility of artefacts due to contamination or polymerase 
errors. Interpretation of the SSCP analysis was by the 
consensus of two investigators. The gel was then transferred 
onto 3 mm Whatmann paper, covered with Saran wrap and 
dried in a vacuum drier at 90°C for one hour. The Saran wrap 
was then replaced by x-ray film and kept at −70°C for 48 hours. 
The mobility shift in DNA bands were visualized by developing 
the x-ray film in a developer. 
Sequencing 
Purified PCR products of the samples showing mobility shift on 
SSCP analysis and randomly chosen normal samples were 
used for direct DNA sequencing, using the automated 'ABI 
prism 310'. To minimize the sequencing artefacts by PCR, 
products from at least two different PCRs were sequenced 
using forward and reverse primers with BigDye terminator cycle 
sequencing ready reaction mix (Applied Biosystems) based on 
fluorescence-labelled dideoxy nucleotides as chain terminators. 
Purified single-stranded extension products were then resolved 
on the ABI Prism 310 sequencer. 
Statistics 
All statistical analysis was performed using SPSS software, 
version 12 (SPSS, Chicago, IL). The chi-square test was used 
to determine associations of the presence of TP53 with various 
clinicopathological parameters and classical risk factors such as 
smoking habit. Statistical significance was considered when 
p≤0.05. 
 
Results 
Forty-two CRC cases were analysed for TP53 gene mutation 
(exon 5–8) by PCR-SSCP followed by sequencing. Analysis of 
these genetic alterations revealed 28 mutations in 19 of 42 
cases analyzed (45%) (Table 2). Among these there were five 
frameshift mutations, 17 transitions and six transversions. 
Frameshift mutations were observed at codon 264 (exon 8), 304 
(exon 8), 297(exon 8), 166 (exon 5) and 174 (exon 5), 
respectively. There were three silent mutations at codon 154 
(exon 5), 222 (exon 6), 224 (exon 6) and two nonsense 
mutations at codon 196 (exon 6) and 192 (exon 6), respectively. 
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Table 2: Details and nature of TP53 mutations in colorectal cancer patients from Kashmir valley 
Analysis of the mutation spectrum revealed a number of salient 
and interesting features, which included high frequency of G:C 
to A:T substitutions. Among the 28 mutations, there were ten in 
exon 5, seven in exon 6, four in exon 7 and seven in exon 8. 
Mutations  at  codon  248  were  detected  in  three  cases,  while 
mutations at codon 175 were detected in two cases (Table 4). 
Our  results  are  consistent  with  previous  reports  on  the 
prevalence of TP53 mutations in CRC ranging from 42% to 67% 
in other parts of the world. Mutation effect data revealed a high 
percentage of missense mutations (23/28) (82.14%) compared 
to frameshift mutations (5/28) (17.85%). Also, mutation pattern 
data of TP53 revealed a high percentage of G:C > A:T (at CpG 
+  non-CpG  sites)  (12/28)  (42.85%)  and  G:C  >  C:G  (3/28) 
(10.71%),  transition  and  transversion  mutations,  respectively. 
All  the  missense  mutations  occurred  in  heterozygous  state 
except one at codon 221, which occurred in homozygous state. 
A significant amount of mutations were found in exon 5 (35.7%), 
exon 6 (25%), exon 7 (14.28%) and exon 8 (25%), respectively. 
Twenty-eight  per  cent  (8/28)  of  the  TP53  mutations  were 
located at hotspot codons 175, 196, 245, 248 and 282, but no 
mutations were detected at the hotspot codon 273. A nonsense 
mutation at codon 196 never reported in colorectal cancer (Arg 
> Stop) was found in one tumour. 
Taking into account classical risk factors and clinicopathological 
parameters  on  the  presence  of  TP53  mutations,  there  was  a 
statistically  significant  increase  (p=0.01;  OR=  6.17;  95% 
CI=1.58-24.05) in the incidence of TP53 mutations in smokers 
rather  than  non-smokers.  A  significantly  higher  frequency  of 
TP53 mutations was seen in rectal (75%) compared with colon 
(18.1%)  cancers  (p=0.01;  OR=0.29;  95%  CI=0.07–1.14).  The 
study also showed a statistically significant increase (p=0.0001;
  4  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h

A
r
t
i
c
l
e

PATIENT  
ID
AGE /  
SEXa
RURAL /  
URBANb
DUKE’S  
STAGEc
SMOKING  
STATUSd
GRADEe SITEf TYPEg NATUREh EXON CODON  
NUMBER
BASE  
CHANGEi
AMINOACID  
CHANGE
EFFECTj
1C 55 / M R C NSk III C AC FAP 5 175 CGC > TGC Arg > Cys MS
2C 72 / M R D NSk III R AC S 5 154 GGC > GGT Gly > Gly MS
7 248 CGG > TGG Arg > Trp MS
5C 68 / F U D NSk II R AC S 7 248 CGG > TGG Arg > Trp MS
8 265 CTG > CCG Leu > Pro MS
8C 62 / F R C Sk I C M S 6 221 GAG > GAC Glu > Asp MS
11C 45 / M R D Sk III R AC S 6 196 CGA > CAA Arg > Stop TP
14C 82 / F U C Sk II R AC S 6 222 CCG > CCC Pro > Pro MS
8 264 CTA > TCTA Leu >>>> FS
16C 51 / M U C Sk II C AC S 5 181 CGC > TGC Arg > Cys MS
6 193 CAT > CGT His > Arg MS
19C 67 / M R D NSk III R AC S 8 282 CGG > TGG Arg > Trp MS
21C 66 / F R C NSk II R AC S 7 245 GGC > AGC Gly > Ser MS
22C 77 / M U B NSk I R AC S 6 202 CGT > CTT Arg > Leu MS
8 272 GTG > ATG Val > Met MS
27C 69 / M R C Sk III R AC S 5 177 CCC > CTC Pro > Leu MS
8 304 ACT > TACT Thr>>>> FS
28C 42 / M U C Sk II R M S 8 261 AGT > AGG Ser > Arg MS
31C 64 / M R C Sk II C AC HNPCC 6 224 GAG > GAA Glu > Glu MS
8 297 CAC > CTAC His >>>> FS
33C 71 / M R D Sk III R AC S 5 171 GAC > CAG Glu > Gln MS
5 174 AGG > AGAG Arg >>>> FS
36C 68 / M R C Sk II R AC S 6 192 CAG > TAG Arg > Stop TP
37C 60 / F U A NSk III R AC S 5 155 ACC > GCC Thr > Ala MS
39C 75 / M U D Sk III R AC S 7 248 CGG > CAG Arg > Gln MS
41C 72 / M R C Sk II R AC S 5 157 GTC > TTC Val > Pro MS
42C 70 / F R C Sk III R AC S 5 166 TCA > ATCA Ser>>>> FS
5 175 CGC > CAC Arg > His MS
Table 2: Details and nature of TP53 mutations in colorectal cancer patients from Kashmir valley
aAge/sex: M = male, F = Female.
bRural/urban: R = rural, U = urban.
cDukes’ stage: A = Tumour confined to the intestinal wall; B = tumour invading through the intestinal wall; C = with lymph node(s) involvement; D = with distant 
metastasis.
dSmoking status: Sk = Smokers; NSk = non-smokers.
eGrade stage: Stage I = T1/T2,N0,M0; Stage II = T3/T4,N0,M0; Stage III = any, N1/N2,M0; Stage IV = AnyT, AnyN,M1.
fSite of tumour: C = Colon, R = rectum.
gTumour type: AC = Adenocarcinoma; M = mucoid.
hNature of tumour: S = Sporadic; FAP = familial adenomatous polyposis; HNPCC = hereditary non-polyposis colorectal cancer.
iBase change: Mutated or inserted nucleotide underlined: + = mutation at CpG site.
jEffect: MS = Missense; FS = frameshift; TP = truncated protein.ecancer 2009, 3:129 
 
Table 3: Association of TP53 gene mutation with clinico-epidemiological features of 19 mutant colorectal cancer patients 
OR=0.03; 95% CI=0.005–0.19) in the incidence of TP53 
mutations in Dukes’ Stage C and D when compared with A and 
B. The comparison did not show significant association with 
age, sex or dwelling (Table 3). In addition, by taking into 
account the specific functional and structural domains of TP53 
affected by the mutations, the cases were also classified as 
follows: four of 19 cases (21%) with mutations of the L3 loop; 
one of 19 cases (5.2%) with mutations of the LSH motif; and 14 
of 19 cases (73.6%) with mutations outside L3 loop and LSH. 
 
Discussion 
Mutations of TP53 are found in approximately half of all CRC 
cases, with a higher frequency observed in distal colon and 
rectal tumours, and a lower frequency in proximal, mucinous 
and MSI+ tumours. Previous analyses on different types of 
tumours have shown that most of the TP53 mutations (~95%) 
affect exons 5–8, which code for residues 130–286, the most 
important region for the folding and, therefore, for the 
stabilization of the tertiary structure of the protein (core domain), 
and which contains the site-specific DNA-binding domain [28]. 
In our screen for mutations in exons 5–8 of TP53 on genomic 
DNA from primary CRCs of 42 patients, we observed a mutation 
frequency of 45.2% (19 of 42), within the fairly wide range of 
values reported previously in CRC (23–61%) [29–34]. This 
variability may be the result of the different methods used to 
assess  TP53 mutations (SSCP, denaturing gradient gel 
electrophoresis, temperature gradient gel electrophoresis and 
direct sequencing), the type of tumour storage (fresh/frozen 
tissue and paraffin embedded blocks), an intrinsic tumoural 
heterogeneity, and, in addition, more specific features of the 
patient cohorts in the study, in particular, histopathological 
staging and grading of the tumour. In fact, patients at an 
advanced Dukes’ stage (C and D) and/or with poorly 
differentiated tumours (G3) generally present a higher rate of 
TP53 mutations [34,35], which correlates with our study. In 
accordance with several other reports [29, 32, 34], 46.4% of all 
of the mutations observed in our series (13 of 28) were in four of 
the five highly conserved areas of the gene, which include two 
important regions for TP53 binding to DNA. One of these 
contains the amino acids needed for DNA interaction, in 
particular those that are part of the L3 Zn-BD and of the LSH 
motif. In our own series, 14.2% (4 of 28) of the mutations 
occurred in L3 and 3.5% (1 of 28) in LSH, in accordance with 
the results reported by Borresen-Dale et al [36]. Our data 
confirm that arginines 248 and 273, which interact directly with 
DNA, are among the most frequently mutated residues (in our 
series: 10% and 0%, respectively). The second region, which 
when mutated results in loss of TP53 DNA-binding capacity 
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Table 4: Mutation profile of the 19 colorectal carcinoma patients 
includes the amino acids located in L2, which are required for 
the folding and stabilization of the central domain [28]. 
Mutations in this area were observed more frequently in our 
own series (28.5%). Mutations at specific codons, such as 
codon 175, may be an indication of specific exposures to toxic 
agents or of genomic susceptibility. It has been observed, 
however, that mutations in codon 175 are more frequent in the 
colon than in the rectum, as previously described by Servomaa 
et al [37], correlating with our study. A peculiarity of the TP53 
mutations in Kashmiri CRC tumours was the lack of deletions 
(0% versus 6.57% in IARC) and a higher prevalence of 
insertions 17.85% versus 1.4% in IARC R12, release). In our 
study, G:C→A:T mutations were more frequent in the CpG sites 
(32.14%) then non-CpG sites (21.42%), nearly matching what 
was reported in the study from Delhi, India (unpublished data, 
personal communication). The high prevalence of G:C→A:T 
mutations was again an observation of interest in our study. 
However, to establish a correlation between the enhanced 
G→A transition (53.56%) and the presence of nitrosamines in 
foodstuffs consumed in Kashmir [38] needs further 
investigation. Alkyl nitrosamines can cause O
6-alkyl guanine 
adducts and base misrepairing during replication, resulting in 
G→A (or C→T on the other strand of the DNA) transition [39] 
and are considered a major risk factor for the Chinese. 
G:C→C:G transition was comparatively high in Kashmiri 
samples (14.28%) versus 7.51% in IARC). The G:C→T:A 
transversion was observed to be confined to males who smoke. 
This type of mutation has been suggested to arise as a result of 
adducts formation at guanosine by metabolites of 
benzo(a)pyrene 7,8-diol-9,10-epoxide, a major tobacco 
carcinogen [40]. Interestingly, in our study, we found 35% of 
mutations occurred at the hotspot codons in rectal tumours as 
opposed to 17% in colon tumours, which is contrary to a 
collaborative study on CRC in which the frequency is 34% and 
41%, respectively [41]. In addition, in our series, the frequency 
of transition and transversion mutations in rectal tumours was 
59% and 23%, respectively, while in colon tumours was 67% 
and 17%, respectively, again contrary to a collaborative study 
on CRC in which there is no difference in the frequency of 
transition and transversion mutations between rectal and colon 
tumours [41]. The reasons for the comparably high frequency of 
transition mutations in colon tumours, and the high frequency of 
transversions in rectal tumours needs further 
investigation. 
 6  www.ecancermedicalscience.com 
R
e
s
e
a
r
c
h
 
A
r
t
i
c
l
e
 ecancer 2009, 3:129 
 
 
Figure 1: Partial electropherograms representing the normal (A) and mutant (B) (shown by asterisk and arrows), profiles in A of exon 5, in B of 
exon 6, in C of exon 7 and in D of exon 8 of TP53. 1A shows the transversion of G to T. 1B shows the transition of A to G. 1C shows the 
transition of G to A. 1D shows the transversion of G to T.
In summary, a significantly higher frequency of TP53 mutations 
was seen in rectal (75%) compared with colon (18.1%) cancers 
(p=0.01; OR= 0.29; 95% CI=0.07–1.14). The reasons for this 
are unknown but may indicate a more important role for TP53 
mutation in the development of rectal compared with colon 
tumours. Also, significantly higher frequencies of TP53 
mutations were seen in smokers rather than non-smokers. 
Interestingly, 70.58% (12/17) of patients who smoke had 
mutations in TP53 (p=0.01) compared to only 28% (7/25) of 
non-smokers. For each site, the more advanced Dukes' C–D 
tumours contained higher frequencies of TP53 mutations 
compared with Dukes' A–B tumours (Table 3). The higher 
frequency of TP53 mutations in Dukes' C–D (77.27%) 
compared with Dukes' A–B (10%) tumours suggests these 
mutations are associated with a more aggressive phenotype. In
support of this, tumours with the poor prognostic features, that 
is vascular or lymphatic invasion, also showed significantly 
higher frequencies of TP53 mutations in the overall CRC cohort 
[42]. 
To sum up, the high frequency of delirious nonsense, frameshift 
and missense mutations observed in the TP53 gene in tumours 
of patients with clinicopathological features such as Dukes' C–D 
and histopathogical grade II and III is a finding that assumes 
significance in view of the fact that these features reflect poor 
prognosis. The study, therefore, suggests TP53 as a potential 
molecular marker and prognostic tool, at least in a subset of 
colorectal tumours. Nevertheless, these observations need 
further investigation on a larger cross section of the colorectal 
cancer patients with relevant controls. 
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